CASSAVA PTI-125-07 rethinkALZ (Phase 3)

Drug Development Trials

About the trial

A phase 3 study investigating the use of Simufilam in mild to moderate Alzheimer’s disease. Simufilam aims to restore healthy cell function of Filamin A, thus disabling the amyloid beta pathway and consequently reduce neuroinflammation. It is administered by oral tablet twice a day.